title: Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran.
abstract: The limited experience in treating patients with extensively drug-resistant tuberculosis (XDR-TB) shows a therapeutic success rate under 50-60% and there are no publications regarding the outcome of these patients treated with standardized regimens. All multidrug-resistant tuberculosis (MDR-TB) patients hospitalized at the Masih Daneshvari Hospital in Tehran, Iran, during 2004-2007 were recruited. Drug susceptibility testing to 14 drugs (including eight second-line drugs) was performed and a standardized regimen with ofloxacin, cycloserine, prothionamide, and amikacin was administered for all patients. Outcome of the patients was studied, comparing between the MDR-TB non-XDR-TB and the XDR-TB. Fifty-one patients were included, 12 with XDR-TB criteria. Of 51, 48 were HIV negative and HIV status was unknown in three cases. All 12 were HIV negative. XDR-TB infection was significantly associated only with age (p = 0.039). The success rates for the total 51 MDR-TB, the 39 MDR-TB non-XDR-TB, and the 12 XDR-TB patients were 76.5% (39 patients), 87.2% (34 patients), and 41.7% (5 patients), respectively. Resistance to ofloxacin, ciprofloxacin, and amikacin were found to be significantly associated with unsuccessful outcome. In this setting, a standardized second-line drugs regimen produces high treatment success rates in MDR-TB patients unless XDR-TB is present.
authors.affiliation: Mycobacteriology Research Center, NRITLD, Shaheed Beheshti University of Medical Science, Tehran, Iran. tabarsi@nritld.ac.ir
authors.forename: Payam
authors.initials: P
authors.lastname: Tabarsi
authors.forename: Ehsan
authors.initials: E
authors.lastname: Chitsaz
authors.forename: Parvaneh
authors.initials: P
authors.lastname: Baghaei
authors.forename: Masoud
authors.initials: M
authors.lastname: Shamaei
authors.forename: Parisa
authors.initials: P
authors.lastname: Farnia
authors.forename: Majid
authors.initials: M
authors.lastname: Marjani
authors.forename: Mehdi
authors.initials: M
authors.lastname: Kazempour
authors.forename: Majid
authors.initials: M
authors.lastname: Amiri
authors.forename: Davood
authors.initials: D
authors.lastname: Mansouri
authors.forename: Mohammad R
authors.initials: MR
authors.lastname: Masjedi
authors.forename: Ali A
authors.initials: AA
authors.lastname: Velayati
authors.forename: Jose A
authors.initials: JA
authors.lastname: Caminero
mesh_terms: D000328:Adult; D000583:Amikacin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002985:Clinical Protocols; D003523:Cycloserine / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007492:Iran; D008297:Male; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D015242:Ofloxacin / Q000627:therapeutic use*; D011515:Prothionamide / Q000627:therapeutic use*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D011515:Prothionamide; D000583:Amikacin; D003523:Cycloserine; D015242:Ofloxacin